Graft versus host disease (GVHD) is one of the major causes of death in patients undergoing
allogeneic hematopoietic stem cell transplantation. Despite prophylactic measures, the
incidence of acute GVHD is estimated at 40-60% among patients receiving transplants from
HLA-identical sibling donors, and may even reach 75% in patients receiving HLA-matched
unrelated transplants. More effective prevention and treatment strategies are needed.
The immunomodulatory and anti-inflammatory properties of Cannabinoids have been shown in
animal models of various inflammatory diseases including multiple sclerosis, inflammatory
bowel disease and rheumatoid arthritis.
Cannabidiol is a major non-psychoactive cannabinoid, which has potent anti-inflammatory and
As such, it may be effective for both prevention and treatment of acute GVHD after allogeneic
stem cell transplantation.